Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2553-2557

  Bitonti, Alan J ^a   Baumann, Russell J ^a   Bush, Tammy L ^a   Cashman, Elizabeth A ^a   Wright, Custer L ^a   Prakash, Nellikunja J ^a  

^a SANOFI   (France)

Author keywords

Breast cancer; Chemoprevention; Clomiphene; Human xenografts; Mammary carcinoma; Tamoxifen; Triphenylethylene

Indexed keywords

CLOMIFENE; DRUG DERIVATIVE; ENCLOMIFENE; ESTROGEN RECEPTOR; MDL 103323; MDL 104890; MDL 104931; MDL 105843; METHYLNITROSOUREA; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLOMIPHENE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029859066     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaboratve Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85, 1992.
2. Jordan, VC: A Current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmoacol 110: 507-517, 1993.
3. Leeuwen FE, Benraadt J. Coebergh JWW, Kiemeney LALM, Gimbrere CHF, Otter R., Schouten LJ, Damhuis RAM. Bontenbal M, Diepenhorst FW, vanden Belt-Dusebout AW and van Tinteren H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. The Lancet 343: 448-452.
4. Jordan VC and Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Europ J Cancer 30A: 1714-1721, 1994.
5. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL. Cronin WM et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
6. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 47: 827-833, 1994.
7. Katzenellenbogen BS Antiestrogen Resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83: 1434-1435, 1991.
8. Chander SK, Sahota SS, Evans TRJ, Luqmani YA: The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit Rev oncol/hematol 15: 243-269, 1993.
9. Wakeling AE, Dukes M and Bowler J: A Potent Specific Pure Antiestrogen with Clinica Potential. Cancer Res 51: 3867-3873, 1991.
10. Van de Velde P, Nique F, Bouchoux F, Bremaud J, Hameau M-C. Lucas D, Moratille C, Viet S, Philibert D and Teutsch G: RU 58668, a New Pure Antiestrogen Inducing a Regression of Human Mammary Carcinoma Implanted in Nude Mice. J Steroid Biochem Molec Biol 48: 187-196, 1994.
11. Beall PT, Misra LK, Young RL, Spjut HJ, Evans HJ and LeBlanc A: Clomiphene protects against osteoporosis in the mature ovariectomized Rat Calcif Tissue Int 36: 123-125, 1984.
12. Fornander T, Rutqvist LE, Sjoberg HE, Blomqvist L, Mattsson An and Glas C: Long-term adjuvant tamoxifen in early breast cancer: Effect on hone mineral density in postmenopausal women. J Clin Oncol 8: 1019-1024, 1990.
13. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A. Williams DC, Cullinan GJ, Bendelc R, Kauffman RF, Bensch WR, Frolik CA, Termine JD and Bryant HU: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized Rats J Clin Invest 93: 63-69, 1994.
14. Gottardis MM and Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced Rat Mammary Carcinoma Model Cancer Res 47: 4020-4024, 1987.
15. Moon RC, Steele VE, Kelloff GJ, Thomas CF, Detrisac CJ, Mehta RG and Lubet RA: Chemoprevention of MNU-Induced mammary tumorigenesis by hormone response of modifiers: Toremifene. RU 16117, Tamoxifen. Aminoglutethimide and Progesterone. Anticancer Res 14: 889-894, 1994.
16. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB and Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88: 123-125, 1996.
17. Herbst AL, Griffiths CT and Kistner RW: Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer chemother Rep 43: 39-41, 1964.
18. Hecker E, Vegh I, Levy CM, Magin CA, Martinez Jc, Loureiro J and Garola RE: Clinical trial of clomiphene in advanced breast cancer. Europ J Cancer 10: 747-749, 1974.
19. Murphy LC and Sutherland RL: Antitumor activity of clomiphene analogs in viiro: Relationship to affinity for the estrogen receptor and another high affinity antiestrogen binding site. J Clin Endocrinol Metabol 57: 373-379.
20. Ruenitz PC, Bagley JR, Watts CKW, Hall RE and Sutherland RL: Substituted-vinyl hydroxytriarylethylenes, 1-[4-]2-(Diethylamino) ethoxy]phenyl]-1-(4-hydroxyphenyl)-2-phenylethylenes: Synthesis and effects on MCF-7 breast cancer cell proliferation. J Med Chem 29: 2511-2519, 1986.
21. Jordan VC, Koch R and Lieberman ME: Structure-activity relationships of nonsteroidal estrogens and antiestrogens. In: Estrogen/antiestrogen action and breast cancer therapy, Ed. VC Jordan, University of Wisconsin Press, Madison, Wisconsin, 1986, pp. 20-41.
22. Ruhinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR: Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
23. Bitonti AJ, Dumont JA, Bush TL, Cashman EA, Cross-Doersen DE, Wright PS, Matthews DP, McCarthy JR and Kaplan DA: Regression of breast tumor xenograft in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 54: 1484-1490, 1994.
24. Sutherland RL and Baulieu EE: Quantitative estimates of cytoplasmic and nuclear oestrogen receptors in chick oviduct. effect of oestrogen on receptor concentration and subcellular distribution. Eur J Biochem 70: 531-536, 1976.
25. Katzenellenbogen JA, Johnson HJ, Jr and Myers HN: Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 12: 4085-4092, 1973.
26. Wakeling AE: Anti-hormones and other steroid analogues. In: Steroid hormones: A practical approach (Eds. B. Green and R.E. Leake), IRL Press, Oxford, 1987, pp. 219-223.
27. Korenman SG: Relation between estrogen inhibitory activity and binding to cytosol of rabbit and human uterus. Endocrinology 87: 1119-1123, 1970.
28. Brunner N, Bronzert D, Vindelev LL, Rygaard K, Spang-Thomsen M and Lippmar ME: Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49: 1515-15, 1989.
29. Thompson HJ and Meeker LD: Induction of mammary gland carcinomas by the subcutaneous injection of 1-methyl-1-nitrosourca. Cancer Res 43: 1628-1629, 1983.
30. Watts CKW, Murphy ALC and Sutherland RL: Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. J Biol Chem 259: 4223-4229, 1984.